-
1
Lung cancer patients face significantly higher risks of severe COVID-19 outcomes, including hospitalization and mortality, compared to the general population.
-
2
COVID-19 vaccines have shown high effectiveness against severe outcomes in the general population, but their effectiveness in lung cancer patients remains unassessed.
-
3
The Omicron variant has a lower mortality risk than previous variants, yet vaccination rates have declined, affecting vulnerable populations like lung cancer patients.
-
4
This study aims to evaluate COVID-19 vaccine effectiveness in reducing severe outcomes among lung cancer patients during the Omicron variant surge.
-
5
The research utilizes a test-negative design to compare severe outcomes in vaccinated versus unvaccinated lung cancer patients in Ontario.
